Get the Flash Player to see this player.
Content Providers
Company News
Zacks, 9/10/2014 - Teva Starts Rolling Submission of its Pain Drug CEP-33237 - Analyst Blog
More Info

Seeking Alpha, 9/10/2014 - Teva: Overlooked And Potentially Undervalued
More Info

Seeking Alpha, 9/10/2014 - Teva: Overlooked And Potentially Undervalued
More Info

In bid to cut costs, Teva to halt R&D in women's health and oncology, 7/10/2014 - In bid to cut costs, Teva to halt R&D in women's health and oncology
More Info

Globes, 6/10/2014 - Teva halts oncology and women's health R&D
Teva is axing 14 pipeline projects to save $550 million over the next three years. More Info

Globes, 8/9/2014 - Partner recognizes Histadrut workers committee
Histadrut chairman: The wave of unionization that we see in the economy is part of the genuine social revolution. More Info

Globes, 7/9/2014 - Strauss to compensate Carmit on Cadbury chocolate
Strauss will pay Carmit NIS 9 million, and buy Carmit products for NIS 50 million following antitrust violations. More Info

Globes, 4/9/2014 - Migdal writes off NIS 7.5m on Dragon Ventures
Migdal Capital Markets closed the hedge fund down after chief investment officer Yaakov Weinstein left. More Info

Globes, 4/9/2014 - Kamada plunges on lung treatment results
The company confirmed that its AAT product for hereditary emphysema did not meet its Phase II/III trial endpoints. More Info

Globes, 4/9/2014 - Bronfman sells 6% stake in Discount Bank
Matthew Bronfman sold the shares for NIS 360 million through Citi. More Info

Globes, 3/9/2014 - Shufersal fires dozens, cuts salaries
CEO Yitzchack Abercohen said the steps will return the chain to growth and prevent continued erosion in financial results. More Info

Globes, 3/9/2014 - Teva reports positive Phase III asthma drug results
Teva will seek FDA and European approval for reslizumab as soon as possible. More Info

Globes, 3/9/2014 - English High Court backs Teva on AstraZeneca inhaler
The ruling against AstraZeneca's patent will facilitate the launch of Teva's DuoResp Spiromax asthma treatment. More Info

Shufersal cutting salaries as it trims down to compete with discounters, 3/9/2014 - Shufersal cutting salaries as it trims down to compete with discounters
More Info

Globes, 1/9/2014 - UBS: Teva hiked Copaxone price 9.9%
Teva is battling generic versions of the 20 mg and 40 mg dosages of its MS blockbuster. More Info

Globes, 1/9/2014 - Osem sells less than Strauss, but earns more
There was marked improvement in Osem’s operations abroad in the first half year. More Info

Globes, 28/8/2014 - Teva recalls Parkinson's drug batch in US
Stability testing found that a batch of carbidopa/levodopa was "superpotent." More Info

Globes, 26/8/2014 - Leumi selling Jewish Colonial Trust stake
Bank Leumi's stake in Jewsih Colonial Trust is worth some NIS 55 million. More Info

Globes, 21/8/2014 - Gazit-Globe to inject NIS 200m into U. Dori
U. Dori Construction expects a NIS 250-350m Q2 loss. More Info

Bank Leumi beats forecasts with smaller loss than expected, 21/8/2014 - Bank Leumi beats forecasts with smaller loss than expected
More Info

Globes, 21/8/2014 - Strauss Q2 profit down 9%
Strauss revenue fell 3.3% in the second quarter because of the shekel's appreciation. More Info

Globes, 19/8/2014 - Delek extends Phoenix sale deadline 45 days
The Gaza operation delayed the arrival of Jared Kushner in Israel. More Info

TheStreet*, 19/8/2014 - Cellcom Israel, Elbit Systems U.S. Shares Immune From Israel Fighting
TEL AVIV (TheStreet) --aFighting has resumed with the end of the latest ceasefire between Israel and Hamas in Gaza,a but the hostilities have had little effect on two Israeli stocks that also trade in the U.S., Cellcom Israel and Elbit Systems . Cellcom Israel, established in 1994, is Israel's biggest cellular provider. Its shares on the New York Stock Exchange, at $11.75, are down nearly 16% for the year to date but up 1.8% for the past 52 weeks. According to the company's Web site it has nearly 3.2 million subscribers and operates on HSPA 3.5 Gen network technology for nationwide coverage. Read More: 10 Stocks Carl Icahn Loves in 2014 Like other Israeli stocks, Cellcom's share price fell at the start ofalatest Gaza conflict that began in July. While the drop was marginal in dollars, it represents a 5.4% drop from the current price and a 16% decline from the high of $13.60 in June, just one month prior to the outbreak of war. However, the stock recovered slowly during July and the early part of August, without any substantial declines. A relatively flat period of trading took place between July 21 and August 15 where the price was fixed in a tight range between $12.15 and $12.25 per share. The stock has a market cap of $1.20 billion and a 52-week range of $10.10 to $14.07. Elbit Systems, meanwhile, gained from the war because it is a global defense electronics company involved in commercial aerospace, military aerospace, command control, land and naval systems, surveillance and reconnaissance. Read More: 7 Stocks Warren Buffett Is Selling in 2014 The company trades both in Tel Aviv and on the Nasdaq. At nearly $59 shares are down 3% for the year to date but up 31% for the past 52 weeks. Shares have been as high as $64.66 on June 9 and as low as $59.16 nearly a month later. The stock has a market cap of $2.6 billion and has traded from a low of $43.11 to $64.66 over the past 52 weeks. a TheStreet Ratings team rates CELLCOM ISRAEL LTD as a Hold with a ratings score of C. TheStreet Ratings Team has this to say about their recommendation: "We rate CELLCOM ISRAEL LTD (CEL) a HOLD. The primary factors that have impacted our rating are mixed ? some indicating strength, some showing weaknesses, with little evidence to justify the expectation of either a positive or negative performance for this stock relative to most other stocks. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations and expanding profit margins. However, as a counter to these strengths, we find that the company has favored debt over equity in the management of its balance sheet." Highlights from the analysis by TheStreet Ratings Team goes as follows: Despite its growing revenue, the company underperformed as compared with the industry average of 4.0%. Since the same quarter one year prior, revenues slightly increased by 1.1%. This growth in revenue appears to have trickled down to the company's bottom line, improving the earnings per share. Net operating cash flow has slightly increased to $131.62 million or 7.89% when compared to the same quarter last year. In addition, CELLCOM ISRAEL LTD has also modestly surpassed the industry average cash flow growth rate of 7.55%. The stock price has risen over the past year, but, despite its earnings growth and some other positive factors, it has underperformed the S&P 500 so far. Despite the fact that it has already risen in the past year, there is currently no conclusive evidence that warrants the purchase or sale of this stock. Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Wireless Telecommunication Services industry and the overall market, CELLCOM ISRAEL LTD's return on equity significantly exceeds that of both the industry average and the S&P 500. The debt-to-equity ratio is very high at 5.34 and currently higher than the industry average, implying increased risk associated with the management of debt levels within the company. Even though the debt-to-equity ratio is weak, CEL's quick ratio is somewhat strong at 1.15, demonstrating the ability to handle short-term liquidity needs. You can view the full analysis from the report here: CEL Ratings Report TheStreet Ratings team rates ELBIT SYSTEMS LTD as a Buy with a ratings score of A-. TheStreet Ratings Team has this to say about their recommendation: "We rate ELBIT SYSTEMS LTD (ESLT) a BUY. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate. The company's strengths can be seen in multiple areas, such as its solid stock price performance, reasonable valuation levels and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had sub par growth in net income." Highlights from the analysis by TheStreet Ratings Team goes as follows: Compared to its closing price of one year ago, ESLT's share price has jumped by 32.93%, exceeding the performance of the broader market during that same time frame. Regarding the stock's future course, although almost any stock can fall in a broad market decline, ESLT should continue to move higher despite the fact that it has already enjoyed a very nice gain in the past year. ELBIT SYSTEMS LTD's earnings per share declined by 10.4% in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, ELBIT SYSTEMS LTD increased its bottom line by earning $4.31 versus $3.98 in the prior year. This year, the market expects an improvement in earnings ($4.43 versus $4.31). The current debt-to-equity ratio, 0.58, is low and is below the industry average, implying that there has been successful management of debt levels. Although the company had a strong debt-to-equity ratio, its quick ratio of 0.80 is somewhat weak and could be cause for future problems. ESLT, with its decline in revenue, slightly underperformed the industry average of 1.3%. Since the same quarter one year prior, revenues slightly dropped by 0.0%. Weakness in the company's revenue seems to have hurt the bottom line, decreasing earnings per share. You can view the full analysis from the report here: ESLT Ratings Report Click to view a price quote on CEL. Click to research the Telecommunications industry. More Info

Globes, 17/8/2014 - Industrial Buildings sells Toronto property for C$60m
The company’s disposable cash flow on the sale is C$32 million. More Info

Globes, 17/8/2014 - Gazit-Globe sells 6 US medical buildings for $205m
Gazit-Globe is realizing assets to focus on retail business operations. More Info

Bank Hapoalim net profits up 19.5%, sets Asia expansion, 15/8/2014 - Bank Hapoalim net profits up 19.5%, sets Asia expansion
More Info

Globes, 14/8/2014 - Bank Hapoalim reports impressive rise in profit
Second quarter profit rose 19.5% from the corresponding quarter to NIS 783 million. More Info

Globes, 13/8/2014 - Mizrahi Tefahot profit up 23% in Q2
Financing revenue rose 5% in the second quarter to NIS 821 millon. More Info

Globes, 13/8/2014 - Elbit Systems wins $80m Latin American C4I deal
The project is part of the Latin American army's extensive modernization program. More Info

Globes, 13/8/2014 - Partner Q2 profit jumps 130% on lower revenue
Partner CEO: The results reflect our ability to cope with intense competition. More Info

Find Company by Name:
Find Company by Industry:
Find Company by Stock Exchange:
Find Company by Index:
language: German French Spanish
Sign-up for free digital directories
Sign-up to receive free newsletter

© Copyright 2014 | Terms & Conditions | Site Map | Contact Us | Tel Aviv Stock Exchange | Find a lawyer in Israel | Find a CPA in Israel | News releases from Israel Created by: Logics - פיתוח תוכנה ואינטרנט

Reprinted from the Equities Israel web site -